HK1183492A1 - 識別 -乙醇酰 神經節苷脂的重組抗體和片段以及其在腫瘤診斷和治療上的應用 - Google Patents
識別 -乙醇酰 神經節苷脂的重組抗體和片段以及其在腫瘤診斷和治療上的應用Info
- Publication number
- HK1183492A1 HK1183492A1 HK13110760.2A HK13110760A HK1183492A1 HK 1183492 A1 HK1183492 A1 HK 1183492A1 HK 13110760 A HK13110760 A HK 13110760A HK 1183492 A1 HK1183492 A1 HK 1183492A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glycolyl
- ganglioside
- tumours
- ana
- diagnosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 150000002270 gangliosides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1183492A1 true HK1183492A1 (zh) | 2013-12-27 |
Family
ID=40261249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13110760.2A HK1183492A1 (zh) | 2003-04-23 | 2013-09-19 | 識別 -乙醇酰 神經節苷脂的重組抗體和片段以及其在腫瘤診斷和治療上的應用 |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1623997B1 (zh) |
JP (1) | JP2006524194A (zh) |
KR (1) | KR20060006937A (zh) |
CN (2) | CN1809592A (zh) |
AR (1) | AR044076A1 (zh) |
AU (1) | AU2004232391B2 (zh) |
BR (1) | BRPI0409664A (zh) |
CA (1) | CA2523449C (zh) |
CL (1) | CL2004000843A1 (zh) |
CR (1) | CR8105A (zh) |
CU (1) | CU23403A1 (zh) |
EA (1) | EA008353B1 (zh) |
ES (1) | ES2535813T3 (zh) |
GE (1) | GEP20084476B (zh) |
HK (1) | HK1183492A1 (zh) |
HR (1) | HRP20050922A2 (zh) |
HU (1) | HUE025266T2 (zh) |
IL (1) | IL171541A (zh) |
LT (1) | LT5353B (zh) |
LV (1) | LV13427B (zh) |
MX (1) | MXPA05011368A (zh) |
MY (1) | MY144620A (zh) |
NZ (1) | NZ543345A (zh) |
PE (1) | PE20050422A1 (zh) |
PL (1) | PL1623997T3 (zh) |
RS (2) | RS51853B (zh) |
SI (1) | SI1623997T1 (zh) |
TN (1) | TNSN05274A1 (zh) |
TW (1) | TWI343923B (zh) |
UY (1) | UY28289A1 (zh) |
WO (1) | WO2004094477A1 (zh) |
ZA (1) | ZA200509457B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4813660B2 (ja) | 1998-11-27 | 2011-11-09 | ダーウィン ディスカバリー リミテッド | 骨鉱化作用を増加するための組成物および方法 |
MEP2808A (xx) | 2003-06-16 | 2010-02-10 | Celltech R & D Inc | Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
WO2011143307A1 (en) | 2010-05-14 | 2011-11-17 | Amgen Inc. | High concentration antibody formulations |
CN103649118A (zh) | 2011-03-01 | 2014-03-19 | 安进公司 | 双特异性结合剂 |
BR112013024493A2 (pt) | 2011-03-25 | 2018-06-26 | Amgen Inc. | cristais de anticorpo antiesclerostina e formulações dos mesmos |
MX355816B (es) | 2011-08-04 | 2018-05-02 | Amgen Inc | Metodo para tratar los defectos de espacio oseo. |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
SG10201509629QA (en) | 2011-12-28 | 2015-12-30 | Amgen Inc | Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies |
CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
CA3009709A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
SG11202003177RA (en) | 2017-10-25 | 2020-05-28 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
BR112020020080A2 (pt) | 2018-03-30 | 2021-01-05 | Amgen Inc | Variantes de anticorpos c-terminais |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
KR102344948B1 (ko) * | 2018-09-03 | 2021-12-28 | 세종대학교산학협력단 | 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4 |
MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | 3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
CN110208409A (zh) * | 2019-06-05 | 2019-09-06 | 中国海洋大学 | 一种乳腺癌的生物标志物及其应用 |
US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
WO2021123908A1 (en) | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
WO1995019790A1 (en) * | 1994-01-25 | 1995-07-27 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
WO1996013594A1 (en) | 1994-10-28 | 1996-05-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Tumor-specific antibody fragments, fusion proteins, and uses thereof |
NZ311174A (en) * | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
-
2003
- 2003-04-23 CU CU20030092A patent/CU23403A1/es unknown
-
2004
- 2004-04-21 PE PE2004000397A patent/PE20050422A1/es not_active Application Discontinuation
- 2004-04-21 CL CL200400843A patent/CL2004000843A1/es unknown
- 2004-04-22 GE GEAP20049062A patent/GEP20084476B/en unknown
- 2004-04-22 BR BRPI0409664-9A patent/BRPI0409664A/pt not_active Application Discontinuation
- 2004-04-22 CN CNA2004800174578A patent/CN1809592A/zh active Pending
- 2004-04-22 JP JP2006504218A patent/JP2006524194A/ja active Pending
- 2004-04-22 AU AU2004232391A patent/AU2004232391B2/en not_active Ceased
- 2004-04-22 MX MXPA05011368A patent/MXPA05011368A/es active IP Right Grant
- 2004-04-22 NZ NZ543345A patent/NZ543345A/en not_active IP Right Cessation
- 2004-04-22 RS YU20050795A patent/RS51853B/en unknown
- 2004-04-22 EP EP04728755.2A patent/EP1623997B1/en not_active Expired - Lifetime
- 2004-04-22 CN CN201210517262.6A patent/CN103012586B/zh not_active Expired - Fee Related
- 2004-04-22 SI SI200432242T patent/SI1623997T1/sl unknown
- 2004-04-22 MY MYPI20041468A patent/MY144620A/en unknown
- 2004-04-22 PL PL04728755T patent/PL1623997T3/pl unknown
- 2004-04-22 KR KR1020057020182A patent/KR20060006937A/ko not_active Application Discontinuation
- 2004-04-22 CA CA2523449A patent/CA2523449C/en not_active Expired - Lifetime
- 2004-04-22 EA EA200501653A patent/EA008353B1/ru not_active IP Right Cessation
- 2004-04-22 TW TW093111267A patent/TWI343923B/zh not_active IP Right Cessation
- 2004-04-22 HU HUE04728755A patent/HUE025266T2/en unknown
- 2004-04-22 RS RS20110319A patent/RS20110319A3/en unknown
- 2004-04-22 WO PCT/CU2004/000006 patent/WO2004094477A1/es active IP Right Grant
- 2004-04-22 ES ES04728755.2T patent/ES2535813T3/es not_active Expired - Lifetime
- 2004-04-23 AR ARP040101389A patent/AR044076A1/es active IP Right Grant
- 2004-04-23 UY UY28289A patent/UY28289A1/es not_active Application Discontinuation
-
2005
- 2005-10-21 HR HR20050922A patent/HRP20050922A2/xx not_active Application Discontinuation
- 2005-10-21 TN TNP2005000274A patent/TNSN05274A1/en unknown
- 2005-10-23 IL IL171541A patent/IL171541A/en active IP Right Grant
- 2005-11-21 LT LT2005101A patent/LT5353B/lt not_active IP Right Cessation
- 2005-11-22 ZA ZA200509457A patent/ZA200509457B/en unknown
- 2005-11-22 LV LVP-05-152A patent/LV13427B/en unknown
- 2005-11-25 CR CR8105A patent/CR8105A/es not_active Application Discontinuation
-
2013
- 2013-09-19 HK HK13110760.2A patent/HK1183492A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1183492A1 (zh) | 識別 -乙醇酰 神經節苷脂的重組抗體和片段以及其在腫瘤診斷和治療上的應用 | |
HK1109160A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
AU2002308348A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
IL174047A0 (en) | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer | |
HK1081448A1 (en) | Bispecific anti-erb-b antibodies and their use in tumor therapy | |
IL173576A0 (en) | Use of polypeptides of the cupredoxin family in cancer therapy | |
IL163563A (en) | Anti-amyloid beta antibodies and their use in medicine | |
PT2940044T (pt) | Anticorpos anti-tnf alfa para utilização em terapia | |
AU2003278807A8 (en) | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | |
EP1572724A4 (en) | KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | |
PL369822A1 (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases | |
AU2003227148A8 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
AU2003255544A8 (en) | Tumor specific oligosaccharide epitopes and use thereof | |
GB0326578D0 (en) | Cancer diagnosis and therapy | |
SI1639013T1 (sl) | Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji | |
AU2003245858A8 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
AU2002346049A1 (en) | Coactivators in the diagnosis and treatment of breast cancer | |
EP1666046A4 (en) | USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES | |
SI1660532T1 (sl) | Fuzijski polipeptidi in njihova uporaba pri antivaskularnem zdravljenju tumorjev | |
AU2003217432A8 (en) | Angiopoietin-1 in the treatment of disease | |
AU2003263036A8 (en) | Span-xb gene and protein for the diagnosis and treatment of cancer | |
AU2003301167A8 (en) | Breast specific protein expressed in cancer and methods of use thereof | |
EP1558085A4 (en) | PROCESS FOR OBTAINING LYMPHOCYTES EXPRESSING INTERLEUKIN 2 AND THEIR USE IN THE TREATMENT OF CANCER | |
GB0219110D0 (en) | Cancer diagnosis and therapy | |
AU2003279864A8 (en) | Methods of use of a dna helicase in the diagnosis and treatment of colon and lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230420 |